The CD95 protein delivers crucial signals for lymphocyte death, and may also negatively regulate T-lymphocyte activation by preventing the influx of calcium ions from the cell’s exterior.

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of ...